196 related articles for article (PubMed ID: 22273580)
1. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
Yu DC; Lee JS; Yoo JY; Shin H; Deng H; Wei Y; Yun CO
Mol Ther; 2012 May; 20(5):938-47. PubMed ID: 22273580
[TBL] [Abstract][Full Text] [Related]
2. FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo.
Jin K; He K; Teng F; Li G; Wang H; Han N; Xu Z; Cao J; Wu J; Yu D; Teng L
Clin Transl Oncol; 2011 Dec; 13(12):878-84. PubMed ID: 22126731
[TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
4. Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus.
Choi IK; Shin H; Oh E; Yoo JY; Hwang JK; Shin K; Yu DC; Yun CO
Int J Cancer; 2015 Nov; 137(9):2253-69. PubMed ID: 25944623
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Jin K; Lan H; Xie B; He K; Xu Z; Li G; Han N; Teng L; Cao F
Cancer Biol Ther; 2012 Jul; 13(9):737-44. PubMed ID: 22617773
[TBL] [Abstract][Full Text] [Related]
6. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of FP3 on a patient-derived tumor tissue xenograft model of rectal carcinoma.
Bi T; Bi T; Lan H; Hu X; Zhu M; Xu Z; Hu J; Teng L; Jin K
Hepatogastroenterology; 2013; 60(128):1950-4. PubMed ID: 24719933
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism.
Jin K; Lan H; Cao F; Xu Z; Han N; Li G; He K; Teng L
Oncol Lett; 2012 May; 3(5):1052-1058. PubMed ID: 22783390
[TBL] [Abstract][Full Text] [Related]
11. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis.
Farzaneh Behelgardi M; Zahri S; Mashayekhi F; Mansouri K; Asghari SM
Sci Rep; 2018 Dec; 8(1):17924. PubMed ID: 30560942
[TBL] [Abstract][Full Text] [Related]
12. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
[TBL] [Abstract][Full Text] [Related]
16. Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Hai-Rong C; Xiang H; Xiao-Rong Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30910851
[TBL] [Abstract][Full Text] [Related]
17. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades.
Lee JH; Choi S; Lee Y; Lee HJ; Kim KH; Ahn KS; Bae H; Lee HJ; Lee EO; Ahn KS; Ryu SY; Lü J; Kim SH
Mol Cancer Ther; 2010 Feb; 9(2):389-99. PubMed ID: 20103598
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of FP3 in a breast cancer xenograft model.
Lan H; Zheng L; Jin K; Teng L
Exp Ther Med; 2013 Jan; 5(1):85-88. PubMed ID: 23251246
[TBL] [Abstract][Full Text] [Related]
19. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
